Ribavirin: all 452 studies that test it
Page 4 of 5. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis CWithdrawnNCT01629732Phase 2
- A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy VolunteersCompletedNCT01615393Phase 1
- Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)CompletedNCT01581203Phase 3
- VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedNCT01581138Phase 2
- Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)CompletedNCT01573351Phase 3
- An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver TransplantationCompletedNCT01571583Phase 3
- Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)WithdrawnNCT01547312Phase 1
- 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS CWithdrawnNCT01517308Phase 3
- A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
- An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)CompletedNCT01513941Phase 3
- Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver TransplantationCompletedNCT01463956Phase 2
- Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)Status unknownNCT01457937Phase 3
- Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve SubjectsCompletedNCT01445795Phase 1/2
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC PolymorphismStatus unknownNCT01441804Phase 3
- GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01435226Phase 2
- GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01434498Phase 2
- Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or RibavirinTerminatedNCT01425970Phase 2
- Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)CompletedNCT01371604Phase 2
- Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01353248Phase 2
- Treatment of Recently Acquired Hepatitis C Virus InfectionCompletedNCT01336010Phase 4
- Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/RibavirinCompletedNCT01335529Phase 2
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedNCT01332955Phase 2
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01309932Phase 2
- Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer PatientsTerminatedNCT01309490Phase 1/2
- Ribavirin Dose Optimization for the Treatment of Hepatitis CCompletedNCT01289496Phase 2
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedNCT01278134Phase 2
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 PatientsCompletedNCT01263860Phase 3
- Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?Status unknownNCT01151397Not applicable
- Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?Status unknownNCT01146626Not applicable
- Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)CompletedNCT01121705Phase 3
- Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid PharmacotherapyCompletedNCT01120795Phase 4
- EXtended Therapy in Hepatitis C Genotype 3 Infected PatientsTerminatedNCT01095445Phase 3
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedNCT01080222Phase 2
- Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01072695Phase 2
- Treatment With Ribavirin for Patients With Metastatic Breast CancerTerminatedNCT01056757Phase 1/2
- PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)Status unknownNCT01056172Phase 4
- Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral TherapyCompletedNCT01045278Phase 4
- Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)CompletedNCT01011166Phase 2
- Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4CompletedNCT01006031Phase 2/3
- Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) RecipientsCompletedNCT00993122Phase 4
- Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment FacilitiesWithdrawnNCT00992693Phase 2
- Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting ConditionsCompletedNCT00960479Phase 1
- Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian EthnicityCompletedNCT00957866Phase 4
- PEG-IFN Plus Ribavirin Combination Therapy for Older PatientsStatus unknownNCT00956982Not applicable
- 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)CompletedNCT00953589Phase 2
- Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis CCompletedNCT00948220Phase 4
- A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis CCompletedNCT00940420Phase 4
- Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
- Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis CCompletedNCT00910975Phase 4
- Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV TreatmentCompletedNCT00909129Not applicable
- Interferon and Ribavirin Treatment in Patients With HemoglobinopathiesStatus unknownNCT00887081Phase 4
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/RelapsersTerminatedNCT00882193Early Phase 1
- Ribavirin for Hemorrhagic Fever With Renal Syndrome in GermanyWithdrawnNCT00868946Phase 2
- Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) InfectionStatus unknownNCT00842205Not applicable
- Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced FibrosisTerminatedNCT00840489Phase 2
- Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)TerminatedNCT00811967Phase 3
- A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis CCompletedNCT00800748Phase 4
- Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)CompletedNCT00788918Not applicable
- PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)CompletedNCT00724620Phase 4
- The Role of Dendritic Cells in Hepatitis C InfectionCompletedNCT00723242Not applicable
- Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus InfectionCompletedNCT00707850Phase 4
- Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus InfectionCompletedNCT00707772Phase 4
- NIDDM and IR in Combination Therapy for CHCCompletedNCT00687999Not applicable
- High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4TerminatedNCT00662220Phase 3
- A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3CompletedNCT00656006Phase 2
- Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and RibavirinTerminatedNCT00641654Phase 4
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 PatientsCompletedNCT00629967Phase 4
- Ribavirin for Hemorrhagic Fever With Renal SyndromeWithdrawnNCT00623168Phase 2
- Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4CompletedNCT00612755Phase 4
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory SyndromeStatus unknownNCT00578825Not applicable
- Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9CompletedNCT00575224Phase 4
- A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.CompletedNCT00560274Phase 4
- A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic LeukemiaCompletedNCT00559091Phase 2
- Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected PatientsCompletedNCT00553930Phase 4
- Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis CCompletedNCT00540345Phase 4
- Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-respondersCompletedNCT00538811Phase 2/3
- Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis CCompletedNCT00527540Phase 3
- Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4CompletedNCT00502099Phase 4
- An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected IndividualsCompletedNCT00489385Phase 1
- Ribavirin, Its Dosing RegimeCompletedNCT00484328Phase 4
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.CompletedNCT00475072Phase 4
- Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment RegimensCompletedNCT00470210Phase 4
- Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver TransplantCompletedNCT00466219Phase 3
- Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and RibavirinTerminatedNCT00456248Phase 4
- Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV TherapyStatus unknownNCT00437476Phase 3
- Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus PioglitazoneCompletedNCT00433069Phase 2
- Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis CCompletedNCT00421434Phase 2/3
- SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.CompletedNCT00412334Phase 4
- Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)CompletedNCT00399672Not applicable
- Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.CompletedNCT00383864Phase 4
- A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.CompletedNCT00377182Phase 2
- A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder SubjectsCompletedNCT00367887Phase 2
- Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol TherapyCompletedNCT00351871Phase 4
- Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 InfectionCompletedNCT00351403Phase 4
- A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis CStatus unknownNCT00332176Phase 2
- A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)CompletedNCT00328549Phase 2
- Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.CompletedNCT00323804Phase 2/3
- NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus CoinfectionCompletedNCT00315432Phase 2
- Chronic Hepatitis C Non-Responder Study With AdoMet and BetaineCompletedNCT00310336Phase 2/3